Changes in liver stiffness and non-invasive markers in chronic hepatitis C virus patients with and without HIV co-infection following interferon-free antiviral treatment.

BACKGROUND AND STUDY AIMS: HIV alone can induce liver fibrosis whereas co-infection with HCV presents a significant challenge in hastening the development of chronic liver disorders such a liver fibrosis, cirrhosis, and hepatic malignancy. Information on the influence of HIV on liver stiffness (LS) after treatment with direct-acting antiviral (DAAs) agents is scarce. The aim of this study was to assess the changes in LS using transient elastography (TE) and fibrosis scores (Fibrosis-4 [FIB-4] and AST-to-platelet ratio index [APRI]) before the initiation of treatment and six months after the end of treatment (EOT) with DAAs in HCV/HIV co-infected patients compared with HCV mono-infected patients.

PATIENTS AND

METHODS

All consecutive chronic HCV patients treated with DAAs during 2016-2020 were retrospectively recruited. TE was performed at baseline and SVR24. Fibrosis scores such as FIB-4 and APRI were calculated in parallel. Improvement of liver fibrosis was defined as any changes in the fibrosis category at baseline to a lower fibrosis category at SVR24.

RESULTS

Of 288 HCV-infected patients, 217 (75.3 %) were HCV mono-infected and 71 (24.7 %) were HCV/HIV co-infected. A significant decrease in TE values was noted at SVR24 compared with baseline (10.3 kPa vs. 7.9 kPa, respectively; P= <0.0001 in HCV mono-infection; 5.9 kPa vs. 5.3 kPa, respectively; P= <0.0001 in HCV/HIV co-infection). Moreover, the proportion of HCV mono-infected patients who had stable, improvement, and worsening in fibrosis stage at follow-up was 50.2 %, 43.3 %, and 6.5 %, respectively while it was 54.9 %, 32.4 %, and 12.7 %, respectively in HCV/HIV co-infection. In multivariable analysis, the higher fibrosis category was the only factor that influenced the improvement of liver fibrosis at follow-up, whereas HIV co-infection wasn't confirmed.

CONCLUSION

patients with HCV mono-infection and HCV/HIV co-infection experienced a rapid and significant improvement in LS and fibrosis indices. This improvement was more pronounced in those with high fibrosis grades at baseline.